STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £102.53m
- £114.46m
- $32.18m
- 18
- 10
- 99
- 33
REG - Shield Therapeutics - Interim results
AnnouncementREG - Shield Therapeutics - ACCRUFeR® Approved by Health Canada
AnnouncementREG - Shield Therapeutics - Notice of interim results
AnnouncementREG - Shield Therapeutics - Unaudited Q2 2024 Trading Update
AnnouncementREG - Shield Therapeutics - Directorate Change
AnnouncementREG - Shield Therapeutics - $5.7m Milestone Monetization Agreement with AOP
AnnouncementREG - Shield Therapeutics - Results of 2024 Annual General Meeting
AnnouncementREG - Shield Therapeutics - New Drug Application for Accrufer® in South Korea
AnnouncementREG - Shield Therapeutics - Audited results for the year ended 31 Dec 2023
AnnouncementREG - Shield Therapeutics - Business Update for Q1 2024
AnnouncementREG - Shield Therapeutics - Notice of Results
AnnouncementREG - Shield Therapeutics - Unaudited Full Year Trading Update
AnnouncementREG - Shield Therapeutics - Appointment of new Chief Financial Officer
AnnouncementREG - Shield Therapeutics - Q3 2023 U.S. Commercial Highlights
AnnouncementREG - Shield Therapeutics - PDMR Transaction Notification
AnnouncementRCS - Shield Therapeutics - Abstract to be presented at Healthcare Conference
AnnouncementREG - Shield Therapeutics - Chief Financial Officer Transition
AnnouncementREG - Shield Therapeutics - Result of REX Retail Offer
AnnouncementREG - Shield Therapeutics - Completion of SWK Financing
Announcement